Treatment options for stage I/II bulky and advanced stage disease have recently extensively changed. For decades in North America, ABVD has been a frontline standard of care option for patients with advanced classical Hodgkin lymphoma (cHL). Recent data on combining brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine demonstrated improved overall survival compared to ABVD but increased adverse events (AEs). We hypothesized that replacing vinblastine with nivolumab (AN+AD) may …